Z6·尊龙凯时

Dr. Jun Zhu, aged 46, has been an executive Director of the Company since August 2023. Dr. Zhu joined the Group in January 2021 and served as senior vice president and chief medical officer of the Company and its subsidiaries. Dr. Zhu served as the president of the Company from November 2021 to April 2023, and the president and chief financial officer of the Company from May 2023 to July 2023. Dr. Zhu served as the chief executive officer, president and chief financial officer of the Company from July 2023 to September 2023, the chief executive officer and chief financial officer of the Company since October 2023 and the chief executive officer of the Company since July 2024. Dr. Zhu serves as the Director and a member of the senior management in certain subsidiaries of the Company.

Prior to joining the Group, Dr. Zhu served as the internal medicine physician in Huashan Hospital affiliated to Fudan University in Shanghai, the project manager and global vice-president of IQVIA Holdings Inc., the general manager (Greater China) of Omnicare Clinical Research Inc., the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology Co., Ltd.* (上海百利佳生醫藥科技有限公司). Mr. Zhu obtained a bachelor’s degree in clinical medicine from Fudan University (復旦大學) in the PRC in July 2001, an EMBA degree from Cheung Kong Graduate School of Business (長江商學院) in the PRC in September 2018, and a doctoral degree in health management from University of Montpellier in France in June 2024.

Mr. Qiyu Chen, aged 52, has been a non-executive Director of the Company since February 2010 and served as the chairman of the Board from December 2018 to November 2021. Mr. Chen joined Fosun Pharma Group in April 1994, and has served as a director of Fosun Pharma since May 2005, and served as the chairman of the board of Fosun Pharma from June 2010 to October 2020. Mr. Chen currently serves as the chairman of the board of Fosun High Tech, the executive director and the co-chief executive officer of Fosun International, the non-executive director and vice chairman of the board of Sinopharm. Mr. Chen previously served as the non-executive director of Gland Pharma, the director of Beijing Sanyuan Foods Co., Ltd.* (北京三元食品股份有限公司) (Shanghai Stock Exchange stock code: 600429) and the co-chairman of the board of New Frontier Health Corporation (delisted from the New York Stock Exchange in January 2022 and merged by Unicorn II Holdings Limited by way of merger by absorption). In addition, Mr. Chen holds directorships in various companies invested by Fosun International and its affiliated companies.

Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association (中國醫藥物資協會), a vice president of China Pharmaceutical Innovation and Research Development Association (中國醫藥創新促進會), the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association (上海市生物醫藥行業協會), a member of the 14th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference, a part time vice chairman of Shanghai Federation of Industry and Commerce (General Chamber of Commerce) (上海市工商業聯合會(總商會)) and the chairman of Biopharmaceutical Chamber of Commerce of Shanghai Federation of Industry and Commerce (上海市工商聯生物醫藥商會). Mr. Chen was awarded “Asia’s Best CEO” by Corporate Governance Asia, etc. Mr. Chen obtained a bachelor’s degree in genetics from Fudan University (復旦大學) in the PRC in July 1993 and a master’s degree in business administration from China Europe International Business School (中歐國際工商學院) in the PRC in September 2005.

Ms. Xiaohui Guan, aged 54, has been a non-executive Director of the Company since December 2018. Ms. Guan joined Fosun Pharma Group in May 2000 and successively served as assistant to the president, general manager of the finance department, chief accountant, vice president and chief accountant, senior vice president and chief financial officer, and executive president and chief financial officer of Fosun Pharma. Ms. Guan has been an executive director of Fosun Pharma since December 2021, and the vice chairman of the board of Fosun Pharma since January 2022. Ms. Guan currently serves as the vice president of Fosun International and the chairman of the board of supervisors of Sinopharm. She was a non-executive director of Sinopharm and Gland Pharma. Moreover, Ms. Guan serves as a director in certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma Group, Ms. Guan worked at the Jiangxi Branch of the Industrial and Commercial Bank of China. Ms. Guan obtained a bachelor’s degree in economics from Jiangxi University of Finance and Economics (江西財經大學) in the PRC in June 2000 and acquired a master’s degree in professional accountancy from the Chinese University of Hong Kong in December 2007. Ms. Guan is qualified as a Chinese Certified Public Accountant and a member of the Association of Chartered Certified Accountants.

Mr. Deyong Wen, aged 53, has been a non-executive Director of the Company since July 2022. Mr. Wen joined Fosun Pharma Group in May 2002 and successively served as vice president, senior vice president, co-president, and president of Fosun Pharma. He has been serving as the chief executive officer of Fosun Pharma since June 2022 and as an executive director of Fosun Pharma since August 2022. Mr. Wen currently serves as a non-executive director of Sinopharm, a director of China National Medicines Corporation Ltd.* (國藥集團藥業股份有限公司) (Shanghai Stock Exchange stock code: 600511), and the chairman of the board of supervisors of China National Accord Medicines Corporation Ltd.* (國藥集團一致藥業股份有限公司) (Shenzhen Stock Exchange stock code: 000028). Mr. Wen served as a director of Anhui Sunhere Pharmaceutical Excipients Co., Ltd.* (安徽山河藥用輔料股份有限公司) (Shenzhen Stock Exchange stock code: 300452). Moreover, Mr. Wen serves as a director of certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma Group, Mr. Wen worked at Chongqing No. 6 Pharmaceutical Factory* (重慶製藥六廠) (the predecessor of Chongqing Yaoyou Pharmaceutical Co., Ltd.* (重慶藥友製藥有限責任公司)). Mr. Wen is currently a deputy of the 16th People’s Congress of Shanghai Municipality, a vice president of Shanghai Licensed Pharmacist Association (上海執業藥師協會), a vice president of China Association of Pharmaceutical Commerce (中國醫藥商業協會), and a member of Chinese Preventive Medicine Association (中華預防醫學會). Mr. Wen graduated from West China University of Medical Sciences (華西醫科大學) (currently known as West China School of Medicine of Sichuan University (四川大學華西醫學中心)) in the PRC in June 1995, and obtained a master’s degree in business administration from Donghua University (東華大學) in the PRC in December 2007.

Dr. Xingli Wang, aged 62, has been a non-executive Director of the Company since August 2023. Dr. Wang joined Fosun Pharma Group in January 2023 and currently serves as the executive president, chief executive officer of the global R&D center, and co-chief executive officer of the Innovative Medicine Business Division of Fosun Pharma. Prior to joining Fosun Pharma Group, Dr. Wang served as a senior lecturer in cardiovascular medicine at The University of New South Wales, Australia, as director of cardiothoracic surgery research and tenured professor at Baylor College of Medicine, USA, and as medical director of Schering-Plough Corporation (a company formerly listed on the NYSE, stock code: SGP; merged into Merck & Co., Inc. in 2009). He also worked at Novartis AG (a company listed on the NYSE, stock code: NVS), mainly serving as project director, global project clinical director, director of Novartis global drug R&D (China), and general manager of the Biomedical Research Institute (China). Dr. Wang obtained a bachelor’s degree in medicine from Shandong Medical College (incorporated into Shandong University in 2000) in the PRC in July 1985 and a doctoral degree in cardiovascular internal medicine from The University of New South Wales in Australia in October 1991. Dr. Wang also holds a license to practice medicine in Australia.

Mr. Tak Young So, aged 54, has been an independent non-executive Director of the Company since September 2019. Mr. So has been the founding and managing partner of FastLane Group since July 2012. He served as an independent non-executive director of CARsgen Therapeutics Holdings Limited (Stock Exchange stock code: 02171) from June 2021 to June 2023 and has been an independent non-executive director of Goodbaby International Holdings Limited (Stock Exchange stock code: 01086) since May 2022.

Mr. So has more than 30 years of experience in finance, accounting, investment, and private equity businesses with global financial institutions and asset management companies. Mr. So served as an auditor at Ernst & Young, Hong Kong, as group audit and project manager of the strategic and performance improvement group in the Sydney office of Commonwealth Bank of Australia, as vice president of global capital market/Asia treasury and vice president of financial controls at Bank of America, Hong Kong, as head of finance and operations of consumer banking in Hong Kong, head of asset and liability management of Greater China/Asia Pacific, and chief financial officer of consumer, commercial and private banking in Hong Kong at ABN AMRO Bank N.V., Hong Kong, as chief financial officer at Hamon Investment Group, an affiliate of Bank of New York Mellon, as chief financial officer of the Asia Pacific of asset management division at Deutsche Bank, Hong Kong, as chief financial officer at PAG Capital, and as a partner at Prospere Capital Limited. Mr. So obtained a bachelor’s degree in accounting and finance and a master’s degree in business administration in banking from the University of Technology Sydney, Australia, in April 1994 and September 1998, respectively. He has been a fellow member of
the Certified Practising Accountants Australia (CPA Australia) since August 2011.

Dr. Guoping Zhao, aged 76, has been an independent non-executive Director of the Company since September 2019. Dr. Zhao is a molecular microbiologist. Currently, he serves as the chairman of the Advisory Committee of the Key Laboratory of Synthetic Biology of the Center for Excellence in Molecular Plant Science of the Chinese Academy of Sciences (CAS) (中國科學院分子植物科學卓越創新中心合成生物學重點實驗室), a professor at the Department of Microbiology and Immunology at the School of Life Sciences of Fudan University (復旦大學生命科學學院微生物學與免疫學系), and the director of the Fudan Microbiome Center (復旦微生物組中心). Dr. Zhao was elected as a member of the Chinese Academy of Sciences (中國科學院院士) in 2005, a fellow of The World Academy of Sciences (發展中國家科學院院士) in 2011, and a member of the American Academy of Microbiology in February 2022. Dr. Zhao is also the honorary president of the Shanghai Society for Microbiology, the honorary president of the Shanghai Society of Biotechnology, the honorary chairman of the Synthetic Biology Committee of the Chinese Society of Biotechnology (中國生物技術學會合成生物學專業委員會), and a member of the American Society for Microbiology.

Dr. Zhao served in various positions related to life science research at the CAS, successively holding roles as a researcher, assistant to the director, and later deputy director of the Microorganism Secondary Metabolism Regulation Laboratory of IPPE, Shanghai Institutes for Biological Sciences (SIBS), CAS (中國科學院上海生命科學研究院植物生理生態研究所次生代謝分子調控研究開放實驗室), as director of the Shanghai Research Center of Biotechnology, CAS (中國科學院上海生物工程研究中心), and as vice president of the SIBS, CAS (中國科學院上海生命科學研究院副院長). Dr. Zhao obtained a bachelor of science degree in microbiology from Fudan University (復旦大學) in Shanghai in the PRC in July 1982 and a Ph.D. degree in biochemistry from Purdue University in the United States in December 1990.

Dr. Ruilin Song (宋瑞霖), aged 62, has been an independent non-executive Director of the Company since September 2019. Dr. Song has been a non-executive director of Luye Pharma Group Ltd.* (綠葉製藥集團有限公司) (Stock Exchange stock code: 02186) since March 2017, an independent non-executive director of Simcere Pharmaceutical Group Limited* (先聲藥業集團有限公司) (Stock Exchange stock code: 02096) since November 2019, an independent non-executive director of Jacobio Pharmaceuticals Group Co., Ltd.* (加科思藥業集團有限公司) (Stock Exchange stock code: 01167) since December 2020, and an independent non-executive director of Mediwelcome Healthcare Management & Technology Inc.* (麥迪衛康健康醫療管理科技股份有限公司) (Stock Exchange stock code: 02159) since December 2020. Dr. Song served as an independent director of Jiangxi Boya Bio-pharmaceutical Co., Ltd.* (江西博雅生物製藥股份有限公司) (Shenzhen Stock Exchange stock code: 300294) from March 2017 to March 2021, an independent director of Shanxi Zhendong Pharmaceutical Co., Ltd.* (山西振東製藥股份有限公司) (Shenzhen Stock Exchange stock code: 300158) from June 2015 to June 2021, an independent director of Tibet Aim Pharm. Inc.* (西藏易明西雅醫藥科技股份有限公司) (Shenzhen Stock Exchange stock code: 002826) from August 2015 to August 2021, and an independent director of Shenzhen Chipscreen Biosciences Co., Ltd.* (深圳微芯生物有限公司) (SSE STAR Market stock code: 688321) from May 2018 to April 2024.

During the time he worked in the Legislative Affairs Office of the State Council, Dr. Song was mainly engaged in the legislative review of Chinese medicine and health laws for 22 years. He participated in all China’s medicine and health legislation activities from 1987 to 2006, in charge of the drafting and review of laws such as Drug Administration Law of the PRC, Law of the PRC on the Prevention and Treatment of Communicable Diseases and Law of the PRC on Medical Practitioners, and administrative regulations such as Regulations on Medical Institutions, Administration of Medical Devices and Emergency Regulations on Public Health Emergencies, etc.

Since 2007, Dr. Song has been dedicated to the research of China’s pharmaceutical policies, especially the policies for pharmaceutical innovation. Under his leadership, Research Center for Medicinal Policy of Chinese Pharmaceutical Association and PhIRDA (中國醫藥創新促進會) have finalised dozens of research projects. Dr. Song has been the executive president of PhIRDA (formerly known as China Pharmaceutical Industry Research and Development Association (中國醫藥工業科研開發促進會)) from November 2009 to September 2019, the president of PhIRDA from September 2019 to September 2020, and executive president of PhIRDA since September 2020. Dr. Song also served as specially-invited expert of Talent Pool Participating in and Discussing State Affairs of the CPPCC, consultant expert of Participating in and Discussing State Affairs of the Chinese Peasants and Workers Democratic Party, executive deputy director of National Drug Policy and Industrial Development Research Center of China Pharmaceutical University, visiting researcher of Shanghai Jiao Tong University, member of Advisory Committee for Traditional Chinese Medicine Strategic Decision of National Medical Products Administration, vice chairman of China Alliance of Rare Diseases (CARD), director of Chinese Pharmacist Association and a member of the Biotech Advisory Panel of the Stock Exchange among other important social positions. Dr. Song obtained a bachelor’s degree in laws from China University of Political Science and Law (中國政法大學) in June 1985, a master’s degree in business administration from China Europe International Business School (中歐國際工商學院) in the PRC in November 2004 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University (中國藥科大學) in December 2018.

Since 2007, Dr. Song has been dedicated to the research of China’s pharmaceutical policies, especially the policies for pharmaceutical innovation. Under his leadership, Research Center for Medicinal Policy of Chinese Pharmaceutical Association and PhIRDA (中國醫藥創新促進會) had finalised dozens of research projects. Dr. Song has been the executive president of PhIRDA (formerly known as China Pharmaceutical Industry Research and Development Association (中國醫藥工業科研開發促進會) from November 2009 to September 2019, the president of PhIRDA from September 2019 to September 2020, and executive president of PhIRDA since September 2020. Dr. Song also served as specially-invited expert of Talent Pool Participating in and Discussing State Affairs of the CPPCC, consultant expert of Participating in and Discussing State Affairs of the Chinese Peasants and Workers Democratic Party, executive deputy director of National Drug Policy and Industrial Development Research Center of China Pharmaceutical University, visiting researcher of Shanghai Jiao Tong University, member of Advisory Committee for Traditional Chinese Medicine Strategic Decision of National Medical Products Administration, expert of the Price and Cost Investigation Center of the National Development and Reform Commission, vice chairman of China Alliance of Rare Diseases (CARD), honorary director of Chinese Pharmaceutical Association (CPA), honorary director of Chinese Pharmacist Association and a member of the Biotech Advisory Panel of the Stock Exchange among other important social positions. Dr. Song obtained a bachelor of laws degree from China University of Political Science and Law (中國政法大學) in June 1985, a master’s degree in business administration from China Europe International Business School (中歐國際工商學院) in the PRC in November 2004 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University (中國藥科大學) in December 2018.